Awakn Life Sciences Corp., a clinical-stage biotech firm specializing in addiction treatment, has entered a licensing partnership with Rivus Wellness and Research Institute, marking its debut in the southern United States. The company's proprietary treatment, Awakn Kare, has shown impressive results in phase II trials, with an 86% abstinence rate post-treatment compared to a 2% rate before treatment. This is a significant improvement over the current standard AUD treatment, which has a 25% abstinence rate.
The licensing agreement, effective from May 2023, grants
Rivus access to Awakn's therapeutics and training. In return, Rivus will pay Awakn an annual fee and a revenue share for each treatment administered. The U.S. addiction treatment market is substantial, with over 14,000 facilities and annual direct medical costs estimated at $30 billion. However, success rates are relatively low, and Awakn is poised to enhance the industry's performance with its more effective treatment options.
Awakn's CEO, Anthony Tennyson, expressed enthusiasm about the partnership with Rivus, highlighting the shared vision and the opportunity to offer a more effective treatment to those in urgent need. Dr. Lane Peyton, from Rivus, also emphasized the potential benefits of the partnership for their patients and the institute's commitment to staying at the forefront of mental health care.
Awakn Life Sciences Corp. is focused on developing therapeutics for
addiction, particularly
Alcohol Use Disorder, which affects millions globally. The company aims to provide innovative treatments to those in desperate need and is working on commercializing its research and development across various platforms.
Rivus Wellness and Research Institute is a team led by Dr. Lane Peyton, offering psychotherapy-based treatments to a diverse population in Oklahoma City. The partnership with Awakn is expected to bring significant advancements in the treatment of mental health and addiction in the region.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
